CYTR - CytRx Corp

Discussion in 'Penny Stocks' started by Biotechmaster, Jan 2, 2020.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    CYTR= Market-Cap $9.8 M--Cash $18.5 M or untill 2023+ --HUGE Pipeline with multiple Phase 3 & Phase 2 programs targeting Rare Disease and Cancer(links to pipeline charts below) . First NDA & MAA submission expected in Q2 for a Rare Disease (Niemann-Pick Disease) with potential approval in Q4 in USA and Europe which will trigger $10 million milestone payment + royalties to CYTR .Multiple clinical trial readouts expected during first half of this year (more infos below).

    This MASSIVE underpriced low float stock could easily rise more than tenfold in the coming months on positive clinical results and approvals . Again Market cap is less than $10 million trading 80% below Cash balance which makes this stock more than a PURE GIFT .STRONG BUY SUPER AGGRESSIVE ,, from current sp its almost a slam dunk .GL


    CytRx (CYTR)

    Market-Cap: $9,8 M
    Cash: $18,5 M ( Cash untill 2023+ )
    Price: $0,29

    Shares Out: 33,6 M

    Burn-rate: only $1.2 M per Quarter
    NO Debt




    Presentation December 2019
    http://www.cytrx.com/wp-content/uploads/2019/12/CYTR-Corp-Overview-December-2019-Non-Conf.pdf



    CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin ....December 19, 2019
    http://www.cytrx.com/wp-content/upl...hlights-TripleNegBreastResultsDec19_FINAL.pdf



    CytRx Corporation - Biopharmaceutical Company Discusses Near Term Value from Out-License Deals and Growth Drivers
    https://stocknewsnow.com/commentary/ANEWSID26062019100002/VIDEO-CytRx-Corporation-(OTCQB-CYTR)



    Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
    https://finance.yahoo.com/news/orphazyme-arimoclomol-receives-us-fast-060058985.html



    Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
    https://finance.yahoo.com/news/orphazyme-receives-breakthrough-therapy-designation-060000973.html


    [​IMG]


    [​IMG]


    [​IMG]


    [​IMG]
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    Market Cap $16 M --Cash $18.5 M or Cash untill 2023+ --NO DEBT --BIG Orphan Drug close to Approval (2H 2020) -three Phase 3 Programs in different Indications ongoing and many in Phase 2 trials -Upcoming MAJOR Milestones + Links to Presentation and Pipeline charts below= The CHEAPEST & BIGGEST Opportunity in the entire Sector ,it has everything to be the minimum next 10+ bagger stock .GL

    CytRx (CYTR)

    Market-Cap: $16 M
    Cash: $18,5 M ( Cash untill 2023+ )
    Price: $0,49

    Shares Out: 33,6 M

    Burn-rate: only $1.2 M per Quarter
    NO DEBT

    Upcoming Catalysts of the Rare Disease Pipeline partnered with Orphazyme (CYTR will get up to $120 M in potential Milestones + Royalties)

    Arimoclomol tested in 4 different indication :

    1) Niemann-Pick disease Type C (NPC)--Early access program in January -- NDA/MAA filing in Q2 2020 ---There are no approved treatments for NPC in the USA and only one approved product in Europe. Arimoclomol has been granted Orphan Drug Designation (EU and USA), Rare Pediatric Disease Designation (USA), and Fast Track designation (USA) for the treatment of NPC.

    2) Sporadic Inclusion Body Myositis (sIBM) Phase 2/3 interim results in Q1 2020 -- very large market potential --There are no approved treatments for sIBM. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of sIBM.

    3) Amyotrophic Lateral Sclerosis (ALS) interim results Q1/Q2 2020 --very large market potential --Currently, there are only limited treatment options available. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of ALS.

    4) Gaucher disease typ III--Phase 2 results in Q1 ---Effective treatments are available for the systemic manifestations of the disease – however, no therapies are available for the neurological symptoms.



    CYTR hits 200 Day MA for the first time since 2017 which is a strong signal
    https://c.stockcharts.com/c-sc/sc?s=CYTR&p=D&yr=3&mn=0&dy=0&i=t0394548873c&r=1578270592760


    CYTR - Arimoclomol --Rare Disease Pipeline (WW rights acquired by Orphazyme)
    [​IMG]

    CYTR-- Aldoxurubicin-- Cancer Pipeline (partnered with ImmunityBio)
    [​IMG]
     
  5. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    EXPLODINGGG again ..still a pure gift under $1

    [​IMG]
     
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    GREAT BUYING OPP here ahead of the BLA acceptance expected next month

    Market Cap $21 M -Cash $14.6 M or Cash for 3 Years / Shares Out 33.6 M / 1 Orphan Drug with potential FDA approval in Q1 / 3 x Phase 3 Programs including 2 potential Blockbusters / has 2 BIG Orphan and Cancer Drug Pipeline / CYTRX has Drug deals worth $460 Million (see presentation below) = One of the MOST cheapest bio gem out there with MASSIV upside potential also a attractive takeover target at this low price .

    Price :0.58

    New Presentation
    http://www.cytrx.com/wp-content/uploads/2020/08/CYTR-Corp-Overview-Q3-2020-Non-Conf.pdf

    Orphan Drug Pipeline
    https://assets.wallstreet-online.de...ot-2020-08-20-cytr-corp-overview-q3-2020-.png

    Cancer Pipeline
    https://assets.wallstreet-online.de...ot-2020-08-20-cytr-corp-overview-q3-2020-.png


    [​IMG]
     

Share This Page